Naratriptan Ratiopharm (Naratriptan)

• Naratriptan is a Triptan indicated for the acute treatment of migraine.
• Migraine without aura: provides rapid relief of headache pain and associated symptoms when taken at the onset of an attack.
• Migraine with aura: reduces the severity of headache and associated nausea when administered early.
• Acute migraine attacks: helps abort the migraine episode and improve functional ability during the attack.

• Naratriptan acts as a selective agonist at 5‑HT1B and 5‑HT1D receptors located on intracranial blood vessels and trigeminal nerve endings. Activation of these receptors causes cranial vasoconstriction and inhibits the release of pro‑inflammatory neuropeptides, thereby interrupting the migraine cascade and relieving headache pain.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Dizziness: transient feeling of light‑headedness.
• Drowsiness: occasional fatigue or sleepiness.
• Dry mouth: reduced salivation.
• Tingling sensations: paresthesia in extremities.
• Fatigue: general lack of energy.

Serious or Rare Side Effects

• Chest pain: possible cardiac ischemia.
• Severe hypertension: sudden rise in blood pressure.
• Serotonin syndrome: agitation, hyperthermia, tremor.
• Allergic reactions: rash, swelling, anaphylaxis.
• Arrhythmias: irregular heart rhythm.
• Myocardial infarction: rare heart attack events.

• Before using Naratriptan, consider the following precautions.
• Cardiovascular disease: avoid if you have coronary artery disease, angina, or history of myocardial infarction.
• Uncontrolled hypertension: do not use if blood pressure is not well managed.
• Liver impairment: use with caution in moderate to severe hepatic dysfunction.
• Concomitant MAO inhibitors: avoid simultaneous use due to risk of serotonin toxicity.
• Pregnancy and lactation: only use if benefits outweigh potential risks.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Naratriptan may interact with several medicines.

Major Interactions (Avoid)

• MAO inhibitors: risk of severe serotonin syndrome.
• SSRIs, SNRIs, or other serotonergic agents: increase serotonin toxicity.
• Ergot alkaloids: additive vasoconstriction may cause ischemia.
• Other triptans: cumulative vasoconstrictive effect.
• Strong CYP1A2 inhibitors: may raise naratriptan plasma levels.

Moderate Interactions (Monitor Closely)

• Antihypertensives: possible reduction in blood pressure control.
• Oral contraceptives: may alter hormonal efficacy.
• CYP3A4 inhibitors (e.g., ketoconazole): modest increase in exposure.
• Antihistamines: may enhance drowsiness.
• Diuretics: monitor electrolytes and blood pressure.